Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Domus Diagnostics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units, representing a decentralized prosecution for the current pending matters. Each application is being reviewed in a different technical environment by a different individual, requiring separate strategies for each case.
GUSSOW, ANNE is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. Since there are 2 pending office actions in total and 2 distinct examiners, each examiner is responsible for 1 active matter. This lack of concentration means that no single examiner's perspective dominates the company's current interactions with the USPTO.
The use of 2 distinct art units for only 2 pending office actions indicates that the company's biotechnology and pharmaceutical innovations are being classified into different specialized categories. For the practitioner, this means there is no overlap in the administrative units or the examiners for the current pending matters. Success in 1 action may not necessarily provide a direct roadmap for the other, given the total diversity in examiners and art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
| STANLEY, JANE L | 1 | 58.2% | +29.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18370117 | RAPID MOLECULAR DIAGNOSTICS WITH UNIFIED-ONE-POT SAMPLE PROCESSING, NUCLEIC ACID AMPLIFICATION, AND RESULT READOUT | GUSSOW, ANNE | — |
| 18205992 | BIOCHEMICAL REACTION TEMPERATURE REGULATOR WITH LIGUID-GAS PHASE CHANGE MATERIAL | STANLEY, JANE L | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1767 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18370117 | RAPID MOLECULAR DIAGNOSTICS WITH UNIFIED-ONE-POT SAMPLE PROCESSING, NUCLEIC ACID AMPLIFICATION, AND RESULT READOUT | GUSSOW, ANNE | 1683 | §103 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18205992 | BIOCHEMICAL REACTION TEMPERATURE REGULATOR WITH LIGUID-GAS PHASE CHANGE MATERIAL | STANLEY, JANE L | 1767 | §102§103DP | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDomus Diagnostics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Anne Gussow has the most, with 1 of Domus Diagnostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
